ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although TKI therapy has revolutionized CML treatment, 25–30 percent of patients with CP-CML have failed TKI treatment, half had mutations in the BCR–ABL1 kinase domain and 50 percent of patients are unknown for the failure of this therapy (Rohrbacher and Hasford, 2009; Baccarani et al., 2013).